Eli Lilly has launched Mounjaro (Tirzepatide) in India, being the first top pharma major to bring out a GLP-1/GIP dual-action weight-loss and diabetes drug into the country.

Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...

More consistent accumulation demonstrated in bloodstream over a one-week duration with once-daily DehydraTECH-tirzepatide oral capsules as compared to once-weekly injection of Zepbound®As previously a ...

University of Chicago researchers assessed the long-term health outcomes and cost-effectiveness of four antiobesity ...

People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...

Compounding pharmacies will have to stop producing copycats of tirzepatide, the active ingredient in the blockbuster weight ...

To be a person in the year 2025 is to encounter, in one way or another, the marketing onslaught for compounded ...

When best friends AnnaLee Canario and Dacia Benjamin started taking weight loss drugs together they thought it would be an ...

Ivim takes a comprehensive approach to obesity care and its customized patient-centric plans are carefully overseen by ...

Novo Nordisk announced headline results from REDEFINE 2, a phase 3 trial in the global REDEFINE programme. REDEFINE 2 is a 68-week efficacy and safety trial investigating ...

(The Hill) – A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight loss and diabetes drugs Zepbound ... an injunction to stop the ...

Bank of America (NYSE:BAC) wrote in a note Thursday that, “Judge Mark Pittman ruled in favor of the U.S. Food and Drug Administration ... not compound tirzepatide, but similar legal challenges around ...